This company has been marked as potentially delisted and may not be actively trading.

ImmunoGen (IMGN) Competitors

IMGN vs. BIIB, UTHR, INCY, NBIX, and IONS

Should you be buying ImmunoGen stock or one of its competitors? The main competitors of ImmunoGen include Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), and Ionis Pharmaceuticals (IONS). These companies are all part of the "biotechnology" industry.

How does ImmunoGen compare to Biogen?

Biogen (NASDAQ:BIIB) and ImmunoGen (NASDAQ:IMGN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk.

: Biogen has a net margin of 13.81% compared to ImmunoGen's net margin of -25.56%. Biogen's return on equity of 12.83% beat ImmunoGen's return on equity.
Company Net Margins Return on Equity Return on Assets
Biogen 13.81% 12.83% 8.01%
ImmunoGen -25.56% -22.11% -13.53%
: Biogen has higher revenue and earnings than ImmunoGen. ImmunoGen is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Biogen $9.89B 2.82 $1.29B $9.32 20.29
ImmunoGen $287.61M 28.91 -$222.93M -$0.31 N/A
: 87.9% of Biogen shares are held by institutional investors. Comparatively, 90.5% of ImmunoGen shares are held by institutional investors. 0.2% of Biogen shares are held by insiders. Comparatively, 5.1% of ImmunoGen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
: Biogen presently has a consensus target price of $214.23, indicating a potential upside of 13.27%. Given Biogen's stronger consensus rating and higher probable upside, analysts clearly believe Biogen is more favorable than ImmunoGen.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biogen
1 Sell rating(s)
13 Hold rating(s)

13 Buy rating(s)

1 Strong Buy rating(s)
2.50
ImmunoGen
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: In the previous week, Biogen had 50 more articles in the media than ImmunoGen. MarketBeat recorded 50 mentions for Biogen and 0 mentions for ImmunoGen. Biogen's average media sentiment score of 0.81 beat ImmunoGen's score of 0.00 indicating that Biogen is being referred to more favorably in the media.
Company Overall Sentiment
Biogen Positive
ImmunoGen Neutral
: Biogen has a beta of 0.19, suggesting that its share price is 81% less volatile than the S&P 500. Comparatively, ImmunoGen has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	13.81%	12.83%	8.01%
ImmunoGen	-25.56%	-22.11%	-13.53%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.89B	2.82	$1.29B	$9.32	20.29
ImmunoGen	$287.61M	28.91	-$222.93M	-$0.31	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	13 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.50
ImmunoGen	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Overall Sentiment
Biogen	Positive
ImmunoGen	Neutral

Summary

Biogen beats ImmunoGen on 13 of the 17 factors compared between the two stocks.

How does ImmunoGen compare to United Therapeutics?

United Therapeutics (NASDAQ:UTHR) and ImmunoGen (NASDAQ:IMGN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk.

: In the previous week, United Therapeutics had 20 more articles in the media than ImmunoGen. MarketBeat recorded 20 mentions for United Therapeutics and 0 mentions for ImmunoGen. United Therapeutics' average media sentiment score of 0.75 beat ImmunoGen's score of 0.00 indicating that United Therapeutics is being referred to more favorably in the media.
Company Overall Sentiment
United Therapeutics Positive
ImmunoGen Neutral
: United Therapeutics presently has a consensus target price of $601.50, indicating a potential upside of 5.12%. Given United Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe United Therapeutics is more favorable than ImmunoGen.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
United Therapeutics
0 Sell rating(s)
3 Hold rating(s)

10 Buy rating(s)

0 Strong Buy rating(s)
2.77
ImmunoGen
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: 94.1% of United Therapeutics shares are held by institutional investors. Comparatively, 90.5% of ImmunoGen shares are held by institutional investors. 10.3% of United Therapeutics shares are held by insiders. Comparatively, 5.1% of ImmunoGen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
: United Therapeutics has higher revenue and earnings than ImmunoGen. ImmunoGen is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
United Therapeutics $3.18B 7.60 $1.33B $27.90 20.51
ImmunoGen $287.61M 28.91 -$222.93M -$0.31 N/A
: United Therapeutics has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500. Comparatively, ImmunoGen has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500.
: United Therapeutics has a net margin of 41.94% compared to ImmunoGen's net margin of -25.56%. United Therapeutics' return on equity of 19.30% beat ImmunoGen's return on equity.
Company Net Margins Return on Equity Return on Assets
United Therapeutics 41.94% 19.30% 17.29%
ImmunoGen -25.56% -22.11% -13.53%

Company	Overall Sentiment
United Therapeutics	Positive
ImmunoGen	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	0 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.77
ImmunoGen	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.18B	7.60	$1.33B	$27.90	20.51
ImmunoGen	$287.61M	28.91	-$222.93M	-$0.31	N/A

Company	Net Margins	Return on Equity	Return on Assets
United Therapeutics	41.94%	19.30%	17.29%
ImmunoGen	-25.56%	-22.11%	-13.53%

Summary

United Therapeutics beats ImmunoGen on 14 of the 16 factors compared between the two stocks.

How does ImmunoGen compare to Incyte?

ImmunoGen (NASDAQ:IMGN) and Incyte (NASDAQ:INCY) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment and risk.

: In the previous week, Incyte had 26 more articles in the media than ImmunoGen. MarketBeat recorded 26 mentions for Incyte and 0 mentions for ImmunoGen. Incyte's average media sentiment score of 0.60 beat ImmunoGen's score of 0.00 indicating that Incyte is being referred to more favorably in the news media.
Company Overall Sentiment
ImmunoGen Neutral
Incyte Positive
: Incyte has a consensus target price of $104.26, indicating a potential upside of 6.97%. Given Incyte's stronger consensus rating and higher probable upside, analysts clearly believe Incyte is more favorable than ImmunoGen.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ImmunoGen
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Incyte
1 Sell rating(s)

10 Hold rating(s)

10 Buy rating(s)

0 Strong Buy rating(s)
2.43
: 90.5% of ImmunoGen shares are owned by institutional investors. Comparatively, 97.0% of Incyte shares are owned by institutional investors. 5.1% of ImmunoGen shares are owned by insiders. Comparatively, 17.8% of Incyte shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
: Incyte has higher revenue and earnings than ImmunoGen. ImmunoGen is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ImmunoGen $287.61M 28.91 -$222.93M -$0.31 N/A
Incyte $5.14B 3.79 $1.29B $7.08 13.77
: ImmunoGen has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500. Comparatively, Incyte has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500.
: Incyte has a net margin of 26.71% compared to ImmunoGen's net margin of -25.56%. Incyte's return on equity of 26.66% beat ImmunoGen's return on equity.
Company Net Margins Return on Equity Return on Assets
ImmunoGen -25.56% -22.11% -13.53%
Incyte 26.71% 26.66% 19.77%

Company	Overall Sentiment
ImmunoGen	Neutral
Incyte	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunoGen	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Incyte	1 Sell rating(s)	10 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.43

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunoGen	$287.61M	28.91	-$222.93M	-$0.31	N/A
Incyte	$5.14B	3.79	$1.29B	$7.08	13.77

Company	Net Margins	Return on Equity	Return on Assets
ImmunoGen	-25.56%	-22.11%	-13.53%
Incyte	26.71%	26.66%	19.77%

Summary

Incyte beats ImmunoGen on 14 of the 16 factors compared between the two stocks.

How does ImmunoGen compare to Neurocrine Biosciences?

ImmunoGen (NASDAQ:IMGN) and Neurocrine Biosciences (NASDAQ:NBIX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment and risk.

: Neurocrine Biosciences has a net margin of 16.73% compared to ImmunoGen's net margin of -25.56%. Neurocrine Biosciences' return on equity of 16.48% beat ImmunoGen's return on equity.
Company Net Margins Return on Equity Return on Assets
ImmunoGen -25.56% -22.11% -13.53%
Neurocrine Biosciences 16.73% 16.48% 11.49%
: In the previous week, Neurocrine Biosciences had 23 more articles in the media than ImmunoGen. MarketBeat recorded 23 mentions for Neurocrine Biosciences and 0 mentions for ImmunoGen. Neurocrine Biosciences' average media sentiment score of 0.87 beat ImmunoGen's score of 0.00 indicating that Neurocrine Biosciences is being referred to more favorably in the news media.
Company Overall Sentiment
ImmunoGen Neutral
Neurocrine Biosciences Positive
: Neurocrine Biosciences has a consensus target price of $180.45, indicating a potential upside of 33.61%. Given Neurocrine Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Neurocrine Biosciences is more favorable than ImmunoGen.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ImmunoGen
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Neurocrine Biosciences
0 Sell rating(s)

5 Hold rating(s)

16 Buy rating(s)

1 Strong Buy rating(s)
2.82
: ImmunoGen has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500. Comparatively, Neurocrine Biosciences has a beta of 0.34, suggesting that its share price is 66% less volatile than the S&P 500.
: Neurocrine Biosciences has higher revenue and earnings than ImmunoGen. ImmunoGen is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ImmunoGen $287.61M 28.91 -$222.93M -$0.31 N/A
Neurocrine Biosciences $2.86B 4.75 $478.60M $4.66 28.98
: 90.5% of ImmunoGen shares are owned by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are owned by institutional investors. 5.1% of ImmunoGen shares are owned by insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
ImmunoGen	-25.56%	-22.11%	-13.53%
Neurocrine Biosciences	16.73%	16.48%	11.49%

Company	Overall Sentiment
ImmunoGen	Neutral
Neurocrine Biosciences	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunoGen	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Neurocrine Biosciences	0 Sell rating(s)	5 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.82

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunoGen	$287.61M	28.91	-$222.93M	-$0.31	N/A
Neurocrine Biosciences	$2.86B	4.75	$478.60M	$4.66	28.98

Summary

Neurocrine Biosciences beats ImmunoGen on 14 of the 17 factors compared between the two stocks.

How does ImmunoGen compare to Ionis Pharmaceuticals?

ImmunoGen (NASDAQ:IMGN) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability.

: Ionis Pharmaceuticals has a consensus target price of $99.35, suggesting a potential upside of 32.03%. Given Ionis Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Ionis Pharmaceuticals is more favorable than ImmunoGen.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ImmunoGen
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Ionis Pharmaceuticals
1 Sell rating(s)

2 Hold rating(s)

17 Buy rating(s)

1 Strong Buy rating(s)
2.86
: ImmunoGen has higher earnings, but lower revenue than Ionis Pharmaceuticals. ImmunoGen is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ImmunoGen $287.61M 28.91 -$222.93M -$0.31 N/A
Ionis Pharmaceuticals $944M 13.17 -$381.39M -$2.07 N/A
: ImmunoGen has a net margin of -25.56% compared to Ionis Pharmaceuticals' net margin of -30.91%. ImmunoGen's return on equity of -22.11% beat Ionis Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
ImmunoGen -25.56% -22.11% -13.53%
Ionis Pharmaceuticals -30.91% -58.65% -10.07%
: 90.5% of ImmunoGen shares are held by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are held by institutional investors. 5.1% of ImmunoGen shares are held by company insiders. Comparatively, 2.7% of Ionis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
: In the previous week, Ionis Pharmaceuticals had 33 more articles in the media than ImmunoGen. MarketBeat recorded 33 mentions for Ionis Pharmaceuticals and 0 mentions for ImmunoGen. Ionis Pharmaceuticals' average media sentiment score of 0.54 beat ImmunoGen's score of 0.00 indicating that Ionis Pharmaceuticals is being referred to more favorably in the news media.
Company Overall Sentiment
ImmunoGen Neutral
Ionis Pharmaceuticals Positive
: ImmunoGen has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 0.38, suggesting that its stock price is 62% less volatile than the S&P 500.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunoGen	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Ionis Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.86

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunoGen	$287.61M	28.91	-$222.93M	-$0.31	N/A
Ionis Pharmaceuticals	$944M	13.17	-$381.39M	-$2.07	N/A

Company	Net Margins	Return on Equity	Return on Assets
ImmunoGen	-25.56%	-22.11%	-13.53%
Ionis Pharmaceuticals	-30.91%	-58.65%	-10.07%

Company	Overall Sentiment
ImmunoGen	Neutral
Ionis Pharmaceuticals	Positive

Summary

Ionis Pharmaceuticals beats ImmunoGen on 10 of the 17 factors compared between the two stocks.

Get ImmunoGen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMGN vs. The Competition

Export

Metric	ImmunoGen	Biotechnology Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.32B	$451.91M	$6.25B	$11.77B
Dividend Yield	N/A	3.86%	2.74%	5.26%
P/E Ratio	-100.74	4.14	29.25	27.07
Price / Sales	28.91	6,879.71	504.68	73.43
Price / Cash	N/A	13.13	43.30	53.90
Price / Book	43.99	77.74	9.67	6.69
Net Income	-$222.93M	-$96.07M	$3.55B	$332.64M

ImmunoGen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMGN ImmunoGen	N/A	$31.23 flat	N/A	N/A	$8.32B	$287.61M	N/A	277
BIIB Biogen	4.0892 of 5 stars	$194.38 +6.0%	$211.81 +9.0%	N/A	$28.53B	$9.89B	22.06	7,500	Earnings Report Analyst Upgrade
UTHR United Therapeutics	3.5485 of 5 stars	$571.07 +0.3%	$601.50 +5.3%	N/A	$25.03B	$3.18B	20.47	1,400	Upcoming Earnings Insider Trade
INCY Incyte	4.0758 of 5 stars	$99.10 +1.4%	$104.26 +5.2%	N/A	$19.72B	$5.14B	15.46	2,844	Earnings Report Analyst Forecast
NBIX Neurocrine Biosciences	3.81 of 5 stars	$131.23 +2.4%	$180.45 +37.5%	N/A	$13.20B	$2.86B	28.16	2,000	Trending News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMGN) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ImmunoGen (IMGN) Competitors

IMGN vs. BIIB, UTHR, INCY, NBIX, and IONS

How does ImmunoGen compare to Biogen?

Summary

How does ImmunoGen compare to United Therapeutics?

Summary

How does ImmunoGen compare to Incyte?

Summary

How does ImmunoGen compare to Neurocrine Biosciences?

Summary

How does ImmunoGen compare to Ionis Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMGN vs. The Competition

ImmunoGen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ImmunoGen (IMGN) Competitors

IMGN vs. BIIB, UTHR, INCY, NBIX, and IONS

How does ImmunoGen compare to Biogen?

Summary

How does ImmunoGen compare to United Therapeutics?

Summary

How does ImmunoGen compare to Incyte?

Summary

How does ImmunoGen compare to Neurocrine Biosciences?

Summary

How does ImmunoGen compare to Ionis Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMGN vs. The Competition

ImmunoGen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools